Terms: = Prostate cancer AND CgA AND Clinical Outcome
3 results:
1. Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide.
Conteduca V; Burgio SL; Menna C; Carretta E; Rossi L; Bianchi E; Masini C; Amadori D; De Giorgi U
Prostate; 2014 Dec; 74(16):1691-6. PubMed ID: 25262981
[TBL] [Abstract] [Full Text] [Related]
2. Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone.
Burgio SL; Conteduca V; Menna C; Carretta E; Rossi L; Bianchi E; Kopf B; Fabbri F; Amadori D; De Giorgi U
Endocr Relat Cancer; 2014 Jun; 21(3):487-93. PubMed ID: 24741024
[TBL] [Abstract] [Full Text] [Related]
3. Chromogranin A and B and secretogranin II in prostatic adenocarcinomas: neuroendocrine expression in patients untreated and treated with androgen deprivation therapy.
Pruneri G; Galli S; Rossi RS; Roncalli M; Coggi G; Ferrari A; Simonato A; Siccardi AG; Carboni N; Buffa R
Prostate; 1998 Feb; 34(2):113-20. PubMed ID: 9465942
[TBL] [Abstract] [Full Text] [Related]
